Company Overview
Serina Therapeutics, Inc. operates as a biotechnology company dedicated to the development of pharmaceutical drugs designed to treat neurological diseases and pain. The company functions within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at unmet medical needs. As of the latest available data, the company maintains a market capitalization of $27.95M and generates $130,000 in annual revenue, though its employee count is not publicly disclosed in the current records. These valuation and revenue figures indicate that Serina Therapeutics is a micro-cap entity operating with a very small revenue base, suggesting it is in an early-stage development phase where capital allocation is primarily directed toward advancing its lead product candidate, SER 252 (POZ-apomorphine), through preclinical stages rather than generating significant commercial sales.
Financial Health
The company reported revenue of $130,000 for the trailing twelve months, while posting a net income of $-19,182,000 and an EBITDA of $-23,949,000, highlighting a substantial gap between revenue and profitability that reveals a cost structure dominated by research, development, and operational expenses typical of pre-commercial biotechnology firms. Free cash flow stands at $-14,704,875, indicating that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity for distribution or debt repayment. The company reports a gross margin of 100.0%, which is characteristic of early-stage biotech firms that have not yet incurred significant cost of goods sold relative to their sales, yet this is contrasted by an operating margin of -18478.5% and a profit margin of 0.0%, signaling severe operational losses relative to the minimal revenue base. On the balance sheet, Serina holds $3.06M in cash against $3.14M in debt, resulting in a debt-to-equity ratio that is not available due to equity dynamics, but the proximity of cash to debt suggests a highly leveraged or cash-neutral position that requires careful monitoring. The current ratio is 1.71, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline of short-term liquidity despite the overall cash burn. Return on equity is reported at -8159.2% and return on assets at -219.6%, metrics that reveal that management effectiveness in generating shareholder value is currently negative, consistent with the capital-intensive nature of developing novel therapies like POZ-lipids in the absence of commercial revenue.
Valuation Assessment
Trailing P/E and forward P/E ratios are presented as N/A and -2.16 respectively, a discrepancy that implies the company has not yet achieved profitability required for traditional earnings-based valuation and that the forward P/E reflects negative earnings expectations in the immediate future. The price-to-book ratio is -4.91, a negative figure that indicates the market capitalization is valued below the company's book value, often seen in distressed or pre-profitable biotechnology companies where tangible assets are outweighed by intangible development risks. Price-to-sales ratio stands at 215.02, and the EV/EBITDA is -1.38, suggesting that the market is pricing the company based on its potential future commercial success and intellectual property value rather than current earnings or sales performance. The 52-week high is $7.92 and the 52-week low is $1.22, placing the current trading environment within a wide volatility range that reflects the speculative nature of the asset class and the uncertainty surrounding the preclinical status of its lead product. The beta value is not available, which prevents a direct comparison of price volatility relative to the broader market, though the wide spread between the high and low prices inherently suggests significant price fluctuation common in small-cap biotechnology stocks.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, indicating that there is no historical growth trajectory available for comparison, which is expected for a company with minimal revenue and no commercial product on the market yet. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, instead choosing to reinvest all available earnings and cash reserves into research and development activities to advance its neurological disease treatments. The overall growth and income profile is defined by a complete reliance on external financing or cash burn to fund operations, with no current income generation or dividend support for shareholders. This profile underscores that the company's primary objective remains product development rather than revenue expansion or income distribution in the near term.